Saturday, October 3, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· March 27, 2026

Canadian Stocks Edge Higher As Markets Turn Cautious Amid Middle East Escalation

View original at nasdaq.com
Canadian Stocks Edge Higher As Markets Turn Cautious Amid Middle East Escalation (RTTNews) - Canadian stocks inched higher on Friday as investors assessed U.S…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The pause period on planned U.S. strikes on Iran's energy plants is extended by 10 days until Monday, April 6

    60% confidence

  • Turkey and Egypt were backing the diplomatic efforts between U.S. and Iran

    60% confidence

  • The U.S. was seeing strong signs that Iran could come for negotiations

    60% confidence

  • The next five years could prove as turbulent as the last

    60% confidence

  • Talks with Iran were ongoing and were productive

    60% confidence

  • The Bank of Canada faces a tough job navigating structural shifts that will permanently reshape the country's economic landscape

    60% confidence

  • The U.S.-Iran talks are going very well despite news outlets reporting to the contrary

    60% confidence

  • U.S.-Iran indirect talks were going on through messages relayed by Pakistan

    60% confidence

  • The U.S. and Iran were having very productive talks

    60% confidence

  • The U.S. had delivered a 15-point peace proposal to Iran through Pakistan

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com